Aleks Guvenel

Aleks Guvenel is Head of Process Development at Quell Therapeutics, where he leads the development and optimisation of the company’s regulatory T cell (Treg) manufacturing platform. He focuses on advancing innovative cell therapy processes, supporting the translation of next-generation Treg therapies from research through to clinical development, with expertise in process development, manufacturing strategy, and technology implementation.